As global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.

Ahead of the Union Budget 2026, pharma players push for API self-reliance and export competitiveness.

In a major relief for blood cancer patients, the state's health department is all set to provide Imatinib tablets ("magic bullet" tablets) ...